Rapid Acute Myeloid Leukemia Targeted Therapy Mutation Panel (3017050)

• Our rapid targeted therapy mutation panel for acute myeloid leukemia (AML) offers a quick turnaround time, which is critical in the timely identification of prognostic markers and advantageous for immediate patient management. The panel assesses regions from nine genes with known clinical significance in hematologic malignancies and therefore aids in the diagnosis of AML subtypes. This panel should be ordered upon initial diagnosis or overt relapse of AML for immediate management guidance. This test is not intended for the detection of minimal residual disease.
• Results are reported within 3 to 7 days.

View more information about this test.

Myeloid Malignancies Mutation and Copy Number Variation Panel by Next Generation Sequencing (3016621)

ARUP’s myeloid malignancies mutation and copy number variation assay by next generation sequencing detects sequence variants, copy number changes (gains or losses), and copy number-neutral loss of heterozygosity (CN-LOH). In addition to targeting specific genes, this panel detects and reports relevant copy number variants (CNVs) down to 5 Mb from across the genome. This test covers all the latest variants relevant for diagnosis and classification, as well as emerging biomarkers that may inform clinical management.

View more information about this test.